If your business develops proprietary formulations, processes or ingredients — and sources any part of its supply chain from China — Beijing's new Five-Year Plan is a document that should land on your IP counsel's desk.

The Plan Names Your Sectors Explicitly

China's 15th Five-Year Plan (2026–2030) commits to decisive technological breakthroughs in advanced materials and biomanufacturing, backed by state-funded R&D growing at more than 7% annually. For companies whose competitive advantage lives in proprietary chemistry, process know-how or biological innovation, this is not background geopolitical noise — it is a direct signal about where Chinese investment and patent activity is heading.

China already dominates global supply of many specialty chemical intermediates, fermentation-derived ingredients and performance material precursors. The plan's ambition is not to build these capabilities — it already has them. The ambition is to move up the value chain, develop proprietary processes, and own the IP that currently sits with Western formulators and technology developers.

The Supply Chain Is Also the IP Exposure Map

Specialty chemical and life science supply chains have run through China for decades, and those relationships carry IP risk that is easy to underestimate. When a U.S. company shares a performance specification with a Chinese toll manufacturer, or sources a process-intensive ingredient from a Chinese producer, technical knowledge transfers. Under normal commercial conditions, contracts and trade secret protections provide some cover. But a state-backed program explicitly designed to formalize that accumulated knowledge into domestically-held patents changes the equation.

Chinese patent filings in chemistry, materials science and biotechnology have grown sharply over the last decade. Most Western companies have not kept pace with that activity in their freedom-to-operate analysis. The Five-Year Plan will accelerate the filing rate further — and the companies that have not conducted a recent landscape search in their technology space may find they are navigating IP they did not know existed.

Process Know-How Is the Most Exposed Asset

In many specialty chemical and life science businesses, the competitive moat is not a single product patent — it is a process: a proprietary synthesis route, a formulation methodology, a fermentation or extraction technique. These innovations are harder to protect comprehensively and easier to replicate incrementally once a manufacturing partner understands the performance targets being pursued.

As Chinese firms and research institutions convert manufacturing experience into formalized IP, US companies whose protection relies primarily on trade secrets or contractual restrictions face growing vulnerability. Those protections erode faster than patents when state-backed programs are specifically designed to develop domestic alternatives.

Competition Beyond China's Borders

The risk is not limited to the Chinese domestic market. The plan places strong emphasis on expanding trade through the Belt and Road Initiative, targeting growth corridors across Southeast Asia, the Middle East and Africa. Chinese producers moving up the value chain — from commodity supplier to application developer — will compete in the same export markets that U.S. specialty chemical and life science companies have historically served, often at Chinese cost structures and backed by state export financing.

A company that today sources an input from a Chinese supplier may find that supplier — or a state-backed successor — competing directly in its end markets within the plan's five-year window.

Three Priorities for IP Counsel

First, conduct a Chinese patent landscape search in your core technology areas. Freedom-to-operate assumptions based on U.S. and European filing activity alone are no longer sufficient. Chinese filings in materials and bioprocessing have reached a volume and sophistication that demands specific attention.

Second, review Chinese supplier and toll manufacturing agreements for IP ownership, specification rights and derivative innovation provisions. Contracts drafted before the current environment may leave meaningful gaps in protection.

Third, assess whether core process innovations are adequately protected by patents filed in China itself. A US patent provides no protection against a Chinese manufacturer producing for Chinese or third-country markets. If the manufacturing or emerging competition is in China, the IP coverage needs to be too.

China's Five-Year Plans get executed — the targets set in the 14th plan for electric vehicles, solar manufacturing and high-speed rail were met or exceeded. Companies that read this one as an IP planning document, rather than a geopolitical news story, will be better positioned when the landscape shifts.